Its comforting to know that they can construct a well presented quarterly report too. Going through the past couple during research were a pleasure - major contracts clearly displayed, highlights clearly in shareholder priority order down the page. Major story of the quarters progress told within top 3 lines that are enough to get the price moving. It seems like common sense - because for companies worth over $200-250M it is a given that you come to expect, although many company's sub $50M just can not for the life of them highlight what progress they made in an order that shareholders care about; "such and such medicine was successful in such and such trial during the quarter" *buried two thirds down the page under what shareholders consider meaningless management commentary regarding the science*. Unfortunately not only confined to biotech micro caps.
Im happy that they have this side of IR down pat. I agree that a well written quarterly report, first line reading 300%+ revenue figure would get this flying. Traders would need but one glance before pulling the trigger.
- Bergen Out
- Major churning at 2.7 average (around $5M bought in at this range, likely 20-30% of current retail holders)
Its primed for a relatively frictionless run come good announcement.
- Forums
- ASX - By Stock
- 4c fair value ($30M), 8c short term target ($60M)
Its comforting to know that they can construct a well presented...
-
- There are more pages in this discussion • 1,327 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NZS (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.334M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
NZS (ASX) Chart |
Day chart unavailable